Navigation Links
Sunesis Pharmaceuticals to Present Interim Clinical Data From Voreloxin (Formerly SNS-595) Ovarian Cancer Trial at 44th ASCO Annual Meeting and Acute Myeloid Leukemia Trials at 13th EHA Congress
Date:5/28/2008

0 YEARS OLD: RESULTS

OF A PHASE 1 STUDY

Abstract #0515

Poster session 2: Acute myeloid leukemia -- Clinical II

Saturday, June 14, 2008, 6:00 p.m. - 7:15 p.m. CEST

o A PHASE 1 TRIAL OF SNS-032, A POTENT AND SPECIFIC CDK 2, 7 AND 9

INHIBITOR, IN CHRONIC LYMPHOCYTIC LEUKEMIA AND MULTIPLE MYELOMA

Abstract #0792

Poster session 2: Novel therapies, drug resistance and pharmacology II

Saturday, June 14, 2008, 6:00 p.m. - 7:15 p.m. CEST

All clinical data presented will be available following each conference on the Sunesis corporate website at http://www.sunesis.com.

About Sunesis' Oncology Programs

Sunesis has built a rich portfolio of product candidates in oncology focused on novel pathways and targets, including inhibition of the cell-cycle and survival signaling.

Sunesis' lead compound, voreloxin (formerly SNS-595), is a novel naphthyridine analog, structurally related to quinolones, a class of compounds which has not been used previously for the treatment of cancer. Voreloxin both intercalates DNA and inhibits topoisomerase II, resulting in replication-dependent, site-selective DNA damage, irreversible G2 arrest and rapid apoptosis. Voreloxin is currently being evaluated in a Phase 2 clinical trial (known as the REVEAL-1 trial) in previously untreated elderly AML patients, in a Phase 1b clinical trial combining voreloxin with cytarabine for the treatment of patients with relapsed/refractory AML, and as a single agent in a Phase 2 clinical trial in platinum-resistant ovarian cancer. In clinical trials conducted to date, voreloxin has been generally well tolerated and has shown objective responses in both solid and hematologic tumor types.

SNS-032, Sunesis' potent and selective inhibitor of cyclin-dependent kinases 2, 7 and 9, is being evaluated in a Phase 1 clinical trial in chronic lymphocytic leuke
'/>"/>

SOURCE Sunesis Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Sunesis Pharmaceuticals Commences Clinical Trials of SNS-595 and SNS-314
2. Sunesis Pharmaceuticals Reports Preliminary SNS-595 Activity in Ovarian Cancer Clinical Trial at AACR-NCI-EORTC International Conference
3. Sunesis Pharmaceuticals to Present Data on Two Product Candidates at the 49th Annual Meeting of the American Society of Hematology
4. Sunesis Pharmaceuticals Reports Positive Interim Data for SNS-595 Single-Agent Activity in Platinum-Resistant Ovarian Cancer
5. Sunesis Pharmaceuticals to Present Non-Clinical Data at the Annual Meeting of the American Association for Cancer Research
6. Sunesis Pharmaceuticals Reports Data from Nonclinical Studies of SNS-032 at the Annual Meeting of the American Association for Cancer Research
7. Sunesis Pharmaceuticals Initiates Phase 2 Clinical Trial of Voreloxin (SNS-595) in Acute Myeloid Leukemia
8. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
9. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
10. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
11. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/30/2014)... CHESTERBROOK, Pa., Oct. 30, 2014   Auxilium ... a fully integrated specialty biopharmaceutical company, today announced ... 30, 2014. The Company highlighted important corporate, commercial, ... "We are very pleased with ... core growth products in our portfolio this quarter, ...
(Date:10/30/2014)... 2014 , Extensively hydrolyzed milk ...   Cow milk protein allergy (CMPA) is the leading cause ... now, it has been managed by eliminating milk proteins ... that it is possible to help build of oral ... children during the first year of life by using ...
(Date:10/30/2014)... 2014 nebulizer is a medical device used ... cystic fibrosis) that converts liquid medication into mist or ... lungs of a patient when inhaled through the mouth ... dominated by various devices powered by electric current and ... COPD and cystic fibrosis and growing number of geriatric ...
Breaking Medicine Technology:Auxilium Pharmaceuticals, Inc. Announces Third Quarter 2014 Financial Results 2Auxilium Pharmaceuticals, Inc. Announces Third Quarter 2014 Financial Results 3Auxilium Pharmaceuticals, Inc. Announces Third Quarter 2014 Financial Results 4Auxilium Pharmaceuticals, Inc. Announces Third Quarter 2014 Financial Results 5Auxilium Pharmaceuticals, Inc. Announces Third Quarter 2014 Financial Results 6Auxilium Pharmaceuticals, Inc. Announces Third Quarter 2014 Financial Results 7Auxilium Pharmaceuticals, Inc. Announces Third Quarter 2014 Financial Results 8Auxilium Pharmaceuticals, Inc. Announces Third Quarter 2014 Financial Results 9Auxilium Pharmaceuticals, Inc. Announces Third Quarter 2014 Financial Results 10Auxilium Pharmaceuticals, Inc. Announces Third Quarter 2014 Financial Results 11Auxilium Pharmaceuticals, Inc. Announces Third Quarter 2014 Financial Results 12Auxilium Pharmaceuticals, Inc. Announces Third Quarter 2014 Financial Results 13Auxilium Pharmaceuticals, Inc. Announces Third Quarter 2014 Financial Results 14Auxilium Pharmaceuticals, Inc. Announces Third Quarter 2014 Financial Results 15Auxilium Pharmaceuticals, Inc. Announces Third Quarter 2014 Financial Results 16Auxilium Pharmaceuticals, Inc. Announces Third Quarter 2014 Financial Results 17Auxilium Pharmaceuticals, Inc. Announces Third Quarter 2014 Financial Results 18Auxilium Pharmaceuticals, Inc. Announces Third Quarter 2014 Financial Results 19Auxilium Pharmaceuticals, Inc. Announces Third Quarter 2014 Financial Results 20Auxilium Pharmaceuticals, Inc. Announces Third Quarter 2014 Financial Results 21Auxilium Pharmaceuticals, Inc. Announces Third Quarter 2014 Financial Results 22Experts Present Latest Research at Allergy Day 2Experts Present Latest Research at Allergy Day 3Nebulizers Market (Pneumatic Nebulizers, Ultrasonic Nebulizers and Mesh Nebulizers) - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2013 - 2019 2Nebulizers Market (Pneumatic Nebulizers, Ultrasonic Nebulizers and Mesh Nebulizers) - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2013 - 2019 3
... 12, 2007 /PRNewswire-FirstCall/ --,InB:Biotechnologies, Inc. ("BioTech"), a ... announced strong positive,results in studies of vaccines ... novel, proprietary AIPwLV(TM) vaccine technology. The,studies were ... Molecular,Biotechnology (CMB), the Contract Research Organization led ...
... LUND, Sweden, March 13, 2007--Active Biotech AB,(Stockholm:ACTI.ST) ... a first human micro-dosing trial of an,I-3D ... was to determine the pharmacokinetic,characteristics of the ... healthy volunteers. , The study demonstrated that ...
Cached Medicine Technology:Integrated Biopharma's Proprietary Vaccine Technology Achieves,Strong Positive Results 2Active Biotech's I-3D Micro-dosing Clinical Trial Concluded 2
(Date:10/30/2014)... October 30, 2014 Sound Telecom, a leader ... that will assist people any time they wonder, “Should I ... right answer by leading them through a series of yes ... their initial query. , There are many considerations and scenarios ... use an answering service . This decision infographic serves ...
(Date:10/30/2014)... HealthDay Reporter WEDNESDAY, Oct. ... chemical during pregnancy may have effects on genital development in ... baby boys born to moms with greater exposure to a ... -- the space between the genitals and anus. Anogenital distance ... of exposure to androgens ("male" hormones) during pregnancy. The ...
(Date:10/30/2014)... 29, 2014 (HealthDay News) -- Eating a low-carb, high-fat ... treat, according to new research. A review ... Atkins diet, that focuses on foods like bacon, eggs, ... reduce seizures in adults whose condition doesn,t improve with ... percent of people with epilepsy whose seizures are not ...
(Date:10/30/2014)... care respects the fact that a patient,s body ... treatment. Over a third of cancer patients experience ... their conditions. And, increasingly, care providers are exploring ... navigate mental health challenges. A University of Colorado ... Psycho-Oncology asks an important question: after ...
(Date:10/29/2014)... October 29, 2014 – Many of the women at first ... most conveyed to researchers why they had not used the ... large HIV prevention trial that, as a likely consequence, did ... to be effective. , The women were among 127 ... called VOICE D, agreed to take part in in-depth interviews ...
Breaking Medicine News(10 mins):Health News:Sound Telecom Produces Decision Infographic to Aid Businesses 2Health News:Plastics' Chemical May Affect Baby Boys' Genital Development 2Health News:Plastics' Chemical May Affect Baby Boys' Genital Development 3Health News:High-Fat, Low-Carb Diet May Help With Tough-to-Treat Epilepsy 2Health News:High-Fat, Low-Carb Diet May Help With Tough-to-Treat Epilepsy 3Health News:Decades of research: Effectiveness of phone counseling for cancer patients still unknown 2Health News:Women who took part in VOICE speak up about why they didn't use HIV prevention products 2Health News:Women who took part in VOICE speak up about why they didn't use HIV prevention products 3
... antibiotics is our best defense against the spread of ... antimicrobial stewardship: a potential cost savings of millions of ... The research is published in the April ... the journal of the Society for Healthcare Epidemiology of ...
... rucksacks for school which top 10 to 15 per cent of ... finds research published online in the Archives of Disease in ... lifestyle, say the researchers. They assessed the back health of ... 11 schools in one province in North Western Spain. The ...
... YORK, MARCH 14, 2012 Researchers have identified a set ... that doctors can use to more accurately predict patients, prognoses ... The study, led by investigators at Memorial Sloan-Kettering Cancer Center, ... New England Journal of Medicine . "Our study ...
... 14 (HealthDay News) -- Doctors with good health habits ... changes to their lifestyle, a new study finds. ... whether they recommend national guideline lifestyle modifications -- such ... alcohol consumption, maintaining a healthy weight and exercising -- ...
... since the mid-1950s particularly since tobacco-control policies and ... on Smoking and Health was released in 1964 ... 2000, according to a study led by researchers at ... Cancer Institute-funded study, conducted by a consortium of six ...
... , WEDNESDAY, March 14 (HealthDay News) -- ... States caused by imported food rose in recent years, ... at the U.S. Centers for Disease Control and Prevention ... Surveillance System between 2005 and 2010. During those five ...
Cached Medicine News:Health News:Monitoring antibiotic use cuts millions in wasteful spending, study finds 2Health News:Heavy rucksacks storing up back problems for many school-kids 2Health News:Genetic profiling can help doctors more accurately predict prognosis and guide treatment decisions for leukemia patients 2Health News:Genetic profiling can help doctors more accurately predict prognosis and guide treatment decisions for leukemia patients 3Health News:Study: US tobacco-control efforts prevented nearly 800,000 cancer deaths between 1975 and 2000 2Health News:Recent Rise Seen in Foodborne Diseases From Imports: CDC 2
... providers can code the charge while completing a ... while away from office, both directly feeding the ... an Encounter Form/Superbill, data entry can be done ... patient payments are posted by reflecting open item ...
... G-3 goniofundus lens incorporate 3 mirrors angled at ... ideal for anterior chamber as well as central ... retinal viewing mirrors are accurately angled and spaced ... fundus. The central portion of the lens ...
The Mid Field 30° lens has a bi-concave design to provide a wider field of view with a 30 degree offset image....
... The Chalam 30° Prism are ... and are recommended for tractional ... and Rhegmatogenus retinal detachment. They ... photocoagulation and other midperipheral laser ...
Medicine Products: